Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China
المؤلفون المشاركون
Xu, Chenjia
Guo, Ruru
Huang, Dandan
Ji, Jian
Liu, Wei
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-08-10
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Background.
The aim of this study was to compare the daily costs and cost effectiveness of fixed combination glaucoma drugs in China.
Methods.
This study included the following fixed combination drugs: brinzolamide 1% and timolol 0.5% (Azarga; Alcon, Inc., Fort Worth, TX, USA), travoprost 0.004% and timolol 0.5% (DuoTrav; Alcon, Inc.), bimatoprost 0.03% and timolol 0.5% (Ganfort; Allergan, Inc., Dublin, Ireland), and latanoprost 0.005% and timolol 0.5% (Xalacom; Pfizer, Inc., New York, NY, USA).
Five bottles of each drug were measured.
The mean actual volume, mean actual number of drops, volume per drop, daily cost, yearly cost, and per mmHg reduction cost for each drug were calculated.
Results.
The volumes per drop ranged from 32.61 ± 2.90 μl (DuoTrav) to 24.38 ± 0.23 μl (Ganfort).
The number of usage days per bottle varied from 36 days (DuoTrav) to 61 days (Ganfort).
Azarga had the lowest daily cost ($0.23) and yearly cost ($84.72), while DuoTrav had the highest daily cost ($0.79) and yearly cost ($287.02).
Azarga costed $2.17–$3.30 per mmHg intraocular pressure reduction, which was lower than the other three drugs.
For the prostaglandin and ß-adrenergic blocker FCs, Ganfort had the lowest daily cost ($0.35) and per mmHg reduction cost (from $3.40 to $4.04).
Conclusions.
The daily costs of these drugs were significantly different, with Azarga having the lowest daily cost and best cost effectiveness.
For the prostaglandin and β-adrenergic blocker fixed combinations, Ganfort was the most economical choice with its lower daily cost and per mmHg reduction cost.
The results of this study could provide drug selection guidance from an economic perspective, but various factors should be considered when making a decision.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Xu, Chenjia& Guo, Ruru& Huang, Dandan& Ji, Jian& Liu, Wei. 2020. Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China. Journal of Ophthalmology،Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1189324
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Xu, Chenjia…[et al.]. Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China. Journal of Ophthalmology No. 2020 (2020), pp.1-5.
https://search.emarefa.net/detail/BIM-1189324
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Xu, Chenjia& Guo, Ruru& Huang, Dandan& Ji, Jian& Liu, Wei. Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China. Journal of Ophthalmology. 2020. Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1189324
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1189324
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر